2025-09-26

【學術亮點】用於選擇性化療的噻吩衍生物的光誘導核易位

字體大小
【學術亮點】用於選擇性化療的噻吩衍生物的光誘導核易位
Intelligent Detection: Smart Agriculture Detection SystemGraduate Institute of Biomedical Engineering / Cheng-Chung Chang / Professor
智慧檢測:智慧農業檢測系統【生醫工程研究所張健忠教授】

 
論文篇名 英文:A photoinduced nuclear translocation of thiophene derivative for selective chemotherapy
中文:用於選擇性化療的噻吩衍生物的光誘導核易位
期刊名稱 Journal of Photochemistry and Photobiology B: Biology
發表年份, 卷數, 起迄頁數 2025, 270, 113223
作者 Dat Thanh Dinh, Yi-Liang Liou, Tzong-Shiun Li, Cheng-Chung Chang(張健忠)*
DOI 10.1016/j.jphotobiol.2025.113223
中文摘要 在這項研究中,製備了一種新型噻吩基有機小分子 2,5-雙(2-(N-丁基吡啶-4-基)乙烯基)-噻吩二碘 (BBT)。BBT不僅對癌細胞具有選擇性暗/光雙細胞毒性,還作為化療劑阿黴素(DXR)的核轉運誘導劑,從而促進抗癌療效。BBT表現出特殊的聚集誘導發射(AIE)效應,並特異性積累在癌細胞的線粒體中,導致癌細胞的暗毒性高於正常細胞。有趣的是,BBT分子在光敏後易位到癌細胞的細胞核中,並進一步選擇性地對癌細胞施加光毒性。由於 BBT 的獨特特性,根據 BBT 和 DXR 之間的多種聯合治療途徑優化了協同療法。根據理論和實際細胞活力率、細胞核中DXR的累積以及核仁片段化所需的時間間隔來評估聯合治療途徑的有效性。BBT預孵育,然後光敏化,然後DXR孵育,被證明是最有效的聯合治療途徑,構成了協同療法。因此,BBT 被認為是一種核易位分子,有利於核靶向化療藥物促進核聚集和藥物療效。此外,由於BBT的核易位行為在癌細胞中具有選擇性,因此可以選擇性地實現化療藥物的核聚集增強。總之,我們開發了一種用於癌症治療的新型協同療法,而 BBT 是 DXR 的潛在化療輔助手段。
英文摘要 In this study, a novel thiophene-based small organic molecule, 2,5-bis(2-(N-butylpyridinium-4-yl)vinyl)-thiophene diiodine (BBT), was prepared. BBT not only presented selective dark/photo dual cell toxicity to cancer cells but also acted as a nuclear transport inducer for the chemotherapy agent doxorubicin (DXR), thereby promoting anticancer efficacy. BBT exhibits the special aggregation-induced emission (AIE) effect and specifically accumulates in the mitochondria of cancer cells, leading to higher dark toxicity in cancer cells than in normal cells. Interestingly, BBT molecules translocate into the nuclei of cancer cells upon photosensitisation and further selectively exert their phototoxicity on cancer cells. Thanks to the unique characteristics of BBT, a synergistic therapy was optimised based on several combinational treatment pathways between BBT and DXR. The effectiveness of the combinational treatment pathway was evaluated based on the theoretical and actual cell viability rates, the accumulation of DXR in cell nuclei, and the required time interval for the fragmentation of nucleoli. BBT pre-incubation, followed by photosensitisation and then DXR incubation, proved to be the most effective combinational treatment pathway, constituting the synergistic therapy. As a result, BBT is considered a nuclear translocation molecule that can be beneficial for nucleus-targetable chemotherapy drugs to promote nuclear aggregation and drug efficacy. Furthermore, because the nuclear translocation behaviour of BBT is selective in cancer cells, the nuclear aggregation enhancement of chemotherapy drugs can be achieved selectively. In conclusion, we developed a novel synergistic therapy for cancer treatment, and BBT is a potential chemotherapy auxiliary for DXR.
發表成果與AI計畫研究主題相關性 本研究著重於利用光學特性分析與訊號處理技術,提升檢測或治療的精準度與效率。該研究中對噻吩基有機小分子的光譜特性、聚集誘導發射效應及其在細胞內定位與行為轉移的追蹤,與本計畫中藉由拉曼光譜技術進行目標物檢測與訊號解析的方式具有相似性。兩者皆涉及多步驟流程優化、目標物選擇性增強及訊號強度提升,對於智慧農業中拉曼檢測的光學系統設計、訊號穩定性與多情境應用具有參考價值。進一步而言,若將相關技術應用於農業,可望提升作物及農產品中農藥殘留與病原檢測的靈敏度與可靠性,並結合自動化與即時數據分析,建立更高效率的智慧農業檢測平台,以確保食品安全並符合國際市場的檢疫需求。
上架日期:2025/7/10
 
聯絡我們